ZYBERNO
Stock Report
Updated Aug 31, 2026

DRUGS MADE IN AMERICA ACQUISITION CORP. (DMAA)

Financial Services • NASDAQ

$10.75

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
DRUGS MADE IN AMERICA ACQUISITION CORP. (DMAA) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

DRUGS MADE IN AMERICA ACQUISITION CORP. (DMAA) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:10.75
Market Cap:$115.21M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$115.44M

Price Action & Momentum (3)

Momentum Percentile:44 / 100
% of 52-Week High:99.9%
B. Profitability Assessment

Return Metrics (4)

ROA:2.8%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-13.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.02x
Quick Ratio:0.02x
Cash Ratio:0.01x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-2,875,440.00
Cash And Cash Equivalents:20,280.00
Long Term Debt:$0.00
Net Debt:$234.13K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$2.63M

Bottom Line Performance (3)

Net income TTM: $6.09M
Linear Growth: -13.1%
📊 Click to view full DMAA Net Income analysis & methodology →
Income Before Tax:$0.00
Ebitda Ttm:-2,633,404.00

Operating Expenses (5)

Operating Expenses:94,574.00
R And D Expense:0.00
Sga Expense:2,633,404.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$146.90M
Current Assets:$69.18K
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:154,309,651.00
Current Liabilities:2,944,624.00
Long Term Debt:$0.00
Short Term Debt:$254.41K

Equity & Capital (3)

Equity:-$7.41M
Retained Earnings:-$7.41M
Common Stock:220,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:254,412.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$379.19K$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$100.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:35,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$0.57

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.05

Book Value & Capital (2)

Book Value Per Share:-$0.69
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Net Income Growth Rate (Linear):-13.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:DMAA
Company Name:DRUGS MADE IN AMERICA ACQUISITION CORP.
Sector:Financial Services
Industry:Blank Checks
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:10.72M
Shares Outstanding Basic:10.72M
Shares Outstanding Diluted:8.57M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 04:08:27 UTC
Data Timestamp:2026-08-18T13:13:45.968198
Scroll to Top